Stockholders' Equity At-the-Market Offering (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Oct. 28, 2021 |
Jul. 14, 2021 |
Mar. 31, 2022 |
Mar. 31, 2021 |
|
Subsidiary, Sale of Stock [Line Items] | ||||
Number of shares authorized to be sold under equity distribution agreement (in shares) | 35,000,000 | |||
Number of common shares issued under equity distribution agreement and outstanding as of period-end (in shares) | 7,502,435 | |||
Accumulated proceeds from issuance of common shares under equity distribution agreement | $ 128,700 | |||
Number of shares of stock issued during period (in shares) | 30,000,000 | 40,000,000 | ||
Issuance of stock, net of offering costs | $ 193,700 | $ 256,500 | $ 323 | $ 99 |
At the Market Offering [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Number of shares of stock issued during period (in shares) | 0 | 0 | ||
Issuance of stock, net of offering costs | $ 0 | $ 0 |
X | ||||||||||
- Definition The number of shares authorized to be sold under an at-the-market Equity Distribution Agreement. No definition available.
|
X | ||||||||||
- Definition Number of shares issued and outstanding as of period-end from an at-the-market common stock offering. No definition available.
|
X | ||||||||||
- Definition Proceeds from (value of) stock issued and outstanding as of period-end from an at-the-market common stock offering. No definition available.
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|